Beclamide

Beclamide
Clinical data
Routes of; administration	By mouth
ATC code	N03AX30 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances);
Identifiers
	IUPAC name N-Benzyl-3-chloropropanamide;
CAS Number	501-68-8 ;
PubChem CID	10391;
ChemSpider	9962 ;
UNII	F5N0ALI65V;
KEGG	D07300 ;
ChEMBL	ChEMBL64195 ;
CompTox Dashboard (EPA)	DTXSID5057755 ;
ECHA InfoCard	100.007.207
Chemical and physical data
Formula	C10H12ClNO
Molar mass	197.66 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	94 °C (201 °F)
	SMILES ClCCC(=O)NCc1ccccc1;
	InChI InChI=1S/C10H12ClNO/c11-7-6-10(13)12-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,12,13) ; Key:JPYQFYIEOUVJDU-UHFFFAOYSA-N ;
	(verify)

Beclamide (marketed as Chloracon, Hibicon, Posedrine, Nydrane, Seclar, and other names) is a drug that possesses anticonvulsant activity.^[2] It is no longer used.

Uses

It has been used as a sedative and as an anticonvulsant.

It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures.

Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia.^[3]

Side effects

Side effects are uncommon but include stomach pain, nervousness, giddiness, skin rash and leukopenia. It is counter-indicated in breast feeding as it is passed in the milk.

References

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP (October 1995). "Metabolism of beclamide after a single oral dose in man: quantitative studies". The Journal of Pharmacy and Pharmacology. 47 (10): 876–8. doi:10.1111/j.2042-7158.1995.tb05757.x. PMID 8583359. S2CID 19556266.
^ Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM (February 1990). "Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide". Acta Psychiatrica Scandinavica. 81 (2): 162–7. doi:10.1111/j.1600-0447.1990.tb06472.x. PMID 2183543. S2CID 26772370.

The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[pmid8583359-2] Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP (October 1995). "Metabolism of beclamide after a single oral dose in man: quantitative studies". The Journal of Pharmacy and Pharmacology. 47 (10): 876–8. doi:10.1111/j.2042-7158.1995.tb05757.x. PMID 8583359. S2CID 19556266.

[pmid2183543-3] Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM (February 1990). "Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide". Acta Psychiatrica Scandinavica. 81 (2): 162–7. doi:10.1111/j.1600-0447.1990.tb06472.x. PMID 2183543. S2CID 26772370.

[1]

[2]

[3]